FDA Grants Accelerated Approval to Iberdomide for Relapsed or Refractory Multiple Myeloma

The U.S. Food and Drug Administration (FDA) granted accelerated approval on August 13, 2026, to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. This decision was supported by data from the phase 3 EXCALIBER-RRMM trial, which demonstrated a statistically significant improvement in minimal residual disease (MRD) negativity rates.